Results 191 to 200 of about 23,762 (225)
Some of the next articles are maybe not open access.
DNA, 1988
High-level expression of human tissue-type plasminogen activator was accomplished in endothelial cells by a novel approach to dihydrofolate reductase (DHFR) coamplification in DHFR+ cells. A tripartite mammalian expression vector coding for DHFR, neomycin phosphotransferase, and the t-PA gene was introduced into bovine endothelial cells by transfection
R W, Connors +9 more
openaire +2 more sources
High-level expression of human tissue-type plasminogen activator was accomplished in endothelial cells by a novel approach to dihydrofolate reductase (DHFR) coamplification in DHFR+ cells. A tripartite mammalian expression vector coding for DHFR, neomycin phosphotransferase, and the t-PA gene was introduced into bovine endothelial cells by transfection
R W, Connors +9 more
openaire +2 more sources
Development of Nonpolyglutamatable DHFR Inhibitors
1999Inhibitors of the enzyme dihydrofolate reductase (DHFR) first came into use as anti-cancer drugs in 1948 when aminopterin (AMT, 1) and methotrexate (MTX, 2) were found to induce temporary remission in children with acute leukemia (1,2). In the five decades that followed this landmark in the history of chemotherapy (3), the term “an-tifolate” or ...
openaire +1 more source
The Journal of Pharmacology and Experimental Therapeutics, 1993
To determine the effect of in vivo pharmacological selective pressure on the insertion and expression of new gene sequences, retroviral-mediated transfer of a methotrexate-resistant dihydrofolate reductase (Mtxr-DHFR) gene in hematopoietic tissue was investigated using a murine syngeneic bone marrow transplant system. A series of recombinant retroviral
D B, Vinh, R S, McIvor
openaire +2 more sources
To determine the effect of in vivo pharmacological selective pressure on the insertion and expression of new gene sequences, retroviral-mediated transfer of a methotrexate-resistant dihydrofolate reductase (Mtxr-DHFR) gene in hematopoietic tissue was investigated using a murine syngeneic bone marrow transplant system. A series of recombinant retroviral
D B, Vinh, R S, McIvor
openaire +2 more sources
Modeling the evolution of drug resistance in Plasmodium falciparum DHFR
2013 IEEE Congress on Evolutionary Computation, 2013Plasmodium falciparum, the causal agent of malaria, has the ability to develop resistance to frontline therapeutics such as chloroquine and sulfadoxine-pyrimethamine rapidly. Here we apply in silico evolution to study and understand the evolutionary trajectories of the clinically relevant therapeutic anti-malaria target dihydrofolate reductase (DHFR ...
Gary B. Fogel, Carla Islas, David Hecht
openaire +1 more source
Origins of Replication and the Nuclear Matrix: The DHFR Domain as a Paradigm
1996The eukaryotic genome appears to be organized in a loopwise fashion by periodic attachment to the nuclear matrix. The proposal that a chromatin loop corresponds to a functional domain has stirred interest in the properties of the DNA sequences at the bases of these loops, the matrix-attached regions (MARs).
P A, Dijkwel, J L, Hamlin
openaire +2 more sources
Pteridinereductase (PTR1);dihydrofolatereductase (DHFR)
2011In vitro studies identified antifolate inhibitors ofLeishmania major Ptr1 that could be used withDhfr inhibitors to help treat parasitic infection. Incultured L. major, five Ptr1-targeting compoundsshowed efficacy against the parasite in combinationwith the Dhfr inhibitor pyrimethamine.
COSTI, Maria Paola, Wade R.
openaire +1 more source
Determining the mechanisms of the allosteric architecture of DHFR
Biophysical Journal, 2023James W. McCormick +3 more
openaire +1 more source
Dihydrofolate Reductase (DHFR) Inhibitors: A Comprehensive Review
Current Medicinal Chemistry, 2023Seyed M Nabavi +2 more
exaly
Rare Congolese Plasmodium falciparum DHFR alleles
Molecular and Biochemical Parasitology, 2005Paul E, Wilson +3 more
openaire +2 more sources

